Advertisement

Current Issues in the Management of Patients with Hodgkin’s Disease

  • Peter H. Wiernik
Part of the Developments in Oncology book series (DION, volume 2)

Abstract

There is currently great and often heated debate over some important aspects of the management of patients with Hodgkin’s disease. New data concerning the proper staging of patients have been developed at several centers, but these data and their implications for staging and management have not been universally accepted. Research at several institutions has indicated that a combined modality approach to some patients with early stage disease offers the best chance of prolonged disease free survival. However, some investigators have argued that overall survival is not enhanced by such aggressive treatment because “salvage” chemotherapy will cure a significant fraction of radiation failures. “Salvage” therapy, however, has not been so effective in all studies. Those who favor the radiotherapy alone approach to all patients with early stage disease argue additionally that the frequency of second malignancies in patients with Hodgkin’s disease is greatest in patients who receive intensive combined modality therapy. Others point out that, while this may be true, closer examination of relevant data demonstrates that the incidence of second malignancies is greatest in patients who receive intensive radiotherapy initially, relapse, and then receive intensive combination chemotherapy as reinduction treatment. It must be noted that such reinduction chemotherapy constitutes “salvage” therapy.

Keywords

Early Stage Disease Combine Modality Combine Modality Therapy Combine Modality Treatment Prolonged Disease Free Survival 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rosenberg, SA, HS Kaplan, E Glatstein, and CS Portlock, The role of adjuvant MOPP in the radiation therapy of Hodgkin’s disease: A progress report after eight years on the Stanford trials. In: Adjuvant Therapy of Cancer, Salmon SS, and SE Jones (eds), -North Holland, p 505–516, 1977Google Scholar
  2. 2.
    Rosenberg, SA, HS Kaplan, E Glatstein, and CS Portlock, The role of adjuvant MOPP in the radiation therapy of Hodgkin’s disease: A progress report after eight years on the Stanford trials. In: Adjuvant Therapy of Cancer, Salmon SS, and SE Jones (eds), -North Holland, p 505–516, 1977Google Scholar
  3. 3.
    Portlock, CS, SA Rosenberg, E Glatstein, and MS Kaplan, Impact of salvage treatment on initial relapses in patients with Hodgkin’s disease, Stages I-III. Blood 51: 825–833, 1978PubMedGoogle Scholar
  4. 4.
    Coleman, CN, CJ Williams, A Flint, et al, Hematologic neoplasia in patients treated for Hodgkin’s disease. New Engl J Med 297: 1249 1252, 1977Google Scholar
  5. 5.
    Cadman, EC, RL Capizzi and JR Bertino, Acute nonlymphocytic leukemia. A delayed complication of Hodgkin’s disease therapy: Analysis of 109 cases. Cancer 40: 1280–1296, 1977PubMedCrossRefGoogle Scholar
  6. 6.
    Cavallin-Stâhl, E, T Landberg, Z Ottow, and F Mitelman, Hodgkin’s disease and acute leukaemia. Scand J Hematol 19: 273–280, 1977CrossRefGoogle Scholar
  7. 7.
    Dick, FR, RD Maca, and R Hankenson, Hodgkin’s disease terminating in a T-cell immunoblastic leukemia. Cancer 42: 1325–1329, 1978PubMedCrossRefGoogle Scholar
  8. 8.
    British National Lymphoma Investigation: Value of prednisone in combination chemotherapy of Stage IV Hodgkin’s disease. Br Med J 3: 413–414, 1975CrossRefGoogle Scholar
  9. 9.
    Peto, R, MC Pike, P Armitage, NE Breslow, et al, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II Analysis and Examples. Brit J Cancer 35: 1–39, 1977PubMedCrossRefGoogle Scholar
  10. 10.
    Levi, JA and PH Wiernik, Limited extranodal Hodgkin’s disease: Unfavorable prognosis and therapeutic implications. Am J Med 63: 365–372, 1977PubMedCrossRefGoogle Scholar
  11. 11.
    Levi, JA, PH Wiernik, and MJ O’Connell, Patterns of relapse in stages I, II and IIIA Hodgkin’s disease: Influence of initial therapy and implications for the future. Int J Rad Oncol 2: 853–862, 1977CrossRefGoogle Scholar
  12. 12.
    Torti, FM, CS Portlock, SA Rosenberg, and HS Kaplan, Extranodal (E) lesions in Hodgkin’s disease (HD): Prognosis and response to therapy. Proc Amer Soc Clin Oncol 19: 367, 1978Google Scholar
  13. 13.
    Mauch, P, R Goodman, and S Hellman, The significance of mediastinal involvement in early stage Hodgkin’s disease. Cancer 42: 1039–1045, 1978PubMedCrossRefGoogle Scholar
  14. 14.
    Lange, B, P Littman, L Schnaufer, and A Evans, Treatment of advanced Hodgkin’s disease in pediatric patients. Cancer 42: 1141–1145, 1978PubMedCrossRefGoogle Scholar
  15. 15.
    Timothy, AR, SBJ Sutcliffe, AG Stanafeld, et al, Radiotherapy in the treatment of Hodgkin’s disease. Br Med J 1: 1216–1249, 1978CrossRefGoogle Scholar
  16. 16.
    Levi, JA, and PH Wiernik, The therapeutic implications of splenic involvement in Stage IIIA Hodgkin’s disease. Cancer 39: 2158–2165, 1977PubMedCrossRefGoogle Scholar
  17. 17.
    Desser, RK, HM Golomb, JE Ultmann, et al, Prognostic classification of Hodgkin’s disease in pathologic stage III, based on anatomic consideration. Blood 49: 883–893, 1977PubMedGoogle Scholar
  18. 18.
    Stein, R, RM Hilborn, JM Flexner, et al, Anatomical substages of stage III Hodgkin’s disease. Cancer 42: 429–436, 1978PubMedCrossRefGoogle Scholar
  19. 19.
    Stein, R, RM Hilborn, JM Flexner, et al, Anatomical substages of stage III Hodgkin’s disease. Cancer 42: 429–436, 1978PubMedCrossRefGoogle Scholar
  20. 20.
    Stein, R, RM Hilborn, JM Flexner, et al, Anatomical substages of stage III Hodgkin’s disease. Cancer 42: 429–436, 1978PubMedCrossRefGoogle Scholar
  21. 21.
    Doniach, I, The effect of radioactive iodine alone and in combination with methylthiouracil and acetylaminofluorene upon tumor production in the rat’s thyroid gland. Br J Cancer 4: 223–234, 1950PubMedCrossRefGoogle Scholar
  22. 22.
    Martin, RG, JC Ruckdeschel, P Chang, et al, Radiation-related pericarditis. Amer J Cardiol 35: 216–220, 1975PubMedCrossRefGoogle Scholar
  23. 23.
    McReynolds, RA, GL Gold, and WC Roberts, Coronary heart disease after mediastinal irradiation for Hodgkin’s disease. Amer J Med 60: 39–45, 1976PubMedCrossRefGoogle Scholar
  24. 24.
    Libshitz, HI, AB Brosof, and ME Southard, Radiographic appearance of the chest following extended field radiation therapy for Hodgkin’s disease. Cancer 32: 206–215, 1973PubMedCrossRefGoogle Scholar
  25. 25.
    doPico GA, AL Wiley Jr, P Rao, and MA Dicksie, Pulmonary reaction to upper mantle radiation therapy for Hodgkin’s disease. Chest 75: 688692, 1979Google Scholar
  26. 26.
    Ray, GR, HW Trueblood, and LP Enright, Oophoropexy: a means of preserving ovarian function following pelvic megavoltage radiotherapy for Hodgkin’s disease. Radiol 96: 175–180, 1970Google Scholar
  27. 27.
    Sherins, RJ, and VT DeVita Jr, Effect of drug treatment for lymphoma on male reproductive capacity. Ann Int Med 79: 216–220, 1973PubMedGoogle Scholar
  28. 28.
    Arseneau, JC, RW Sponzo, DL Levin, et al, Nonlymphomatous malignant tumors complicating Hodgkin’s disease. Possible association with intensive therapy. N Engl J Med 287: 1119–1122, 1972PubMedCrossRefGoogle Scholar
  29. 29.
    DeVita, VT, AA Serpick, and PP Carbone, Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 73: 88 1895, 1970Google Scholar
  30. 30.
    DeVita, V, GP Cannellos, S Hubbard, et al, Chemotherapy of Hodgkin’s disease (HD) with MOPP: A 10 year progress report. Proc Amer Soc Clin Oncol 17: 269, 1976Google Scholar
  31. 31.
    Owen, CML, E Katongole-Mbidde, C Mire, et al, Childhood Hodgkin’s disease in Uganda: A ten year experience. Cancer 42: 787–792, 1978CrossRefGoogle Scholar
  32. 32.
    Owen, CML, E Katongole-Mbidde, C Mire, et al, Childhood Hodgkin’s disease in Uganda: A ten year experience. Cancer 42: 787–792, 1978CrossRefGoogle Scholar
  33. 33.
    Hoppe, RT, CS Portlock, E Glatstein, et al, Alternating chemotherapy and irradiation in the treatment of advanced Hodgkin’s disease. Cancer 43: 472–481, 1979PubMedCrossRefGoogle Scholar
  34. 34.
    Goodman, RL, AJ Piro, and S Hellman, Can pelvic irradiation be omitted in patients with pathologic stages IA and IIA Hodgkin’s disease? Cancer 37: 2834–2839, 1976PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers bv, The Hague 1980

Authors and Affiliations

  • Peter H. Wiernik
    • 1
  1. 1.Baltimore Cancer Research Program of the Division of Cancer TreatmentNational Cancer Institute at the University of Maryland HospitalBaltimoreUSA

Personalised recommendations